Finerenone in Patients with CKD and T2D by SGLT2i Treatment: An Analysis of the FIDELIO-DKD Study

被引：0
|
作者：
Rossing, Peter
Agarwal, Rajiv
Anker, Stefan
Filippatos, Gerasimos
Pitt, Bertram
Ruilope, Luis M.
Chan, Juliana C.
Kooy, Adriaan
Mccafferty, Kieran
Schernthaner, Guntram
Wanner, Christoph
Joseph, Amer
Scheerer, Markus F.
Scott, Charlie
Bakris, George
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-14-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
14-LB
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Finerenone in Patients across the Spectrum of CKD and T2D by GLP-1RA Use
    Rossing, Peter
    Anker, Stefan
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Fonseca, Vivian
    Umpierrez, Guillermo E.
    Caramori, Luiza
    Lambelet, Marc
    Viswanathan, Prabhakar
    Lawatscheck, Robert
    Joseph, Amer
    Bakris, George
    DIABETES, 2022, 71
  • [32] Eligibility and Utilization of SGLT2i and GLP1-RA in T2D by Cardiovascular and Renal Indications
    Blood, Alexander
    Chang, Lee-Shing
    Colling, Caitlin A.
    Gabovitch, Daniel
    Hamersky, Carol M.
    Durden, Emily
    Holt, Cassie
    Noone, Joshua
    Cannon, Christopher P.
    Wexler, Deborah J.
    Scirica, Benjamin M.
    Waterman, Fanta
    Stern, Gretchen
    Zelle, David
    DIABETES, 2022, 71
  • [33] CHARACTERISTICS OF FINERENONE INITIATORS AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) AND TYPE 2 DIABETES (T2D)
    Teng, Chia-Chen
    Singh, Rakesh
    Kong, Sheldon
    Djaraher, Rachel
    Williamson, Todd
    Farej, Ryan
    Willey, Vincent
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S75 - S75
  • [34] Rapid improvement of glycemic control in adolescent with type 2 diabetes (T2D) after treatment with a SGLT2i inhibitor: a case report
    Castorani, V.
    Savastio, S.
    Pozzi, E.
    Demichelis, M.
    Medina, F.
    Rabbone, I.
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 275 - 276
  • [35] Safety of SGLT2i with regard to bone and mineral metabolism in patients with CKD
    Kaze, Arnaud D.
    Patorno, Elisabetta
    Paik, Julie M.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2023, 32 (04): : 324 - 329
  • [36] Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD
    Sato, Atsuhisa
    Nishimoto, Mitsuhiro
    HYPERTENSION RESEARCH, 2025,
  • [37] ADVANCING DKD AND CKD TREATMENT WITH SGLT2 INHIBITORS AND KERENDIA
    Staudt, Meghan
    Pearson-Bey, Charisse
    Robinson, Jennifer
    Hurtado, Tucker
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (04) : S105 - S105
  • [38] Outcomes with Finerenone in People with CKD and T2D by Baseline Insulin Resistance-A FIDELITY Subgroup Analysis
    Ebert, Thomas
    Anker, Stefan
    Ruilope, Luis M.
    Fioretto, Paola
    Fonseca, Vivian
    Umpierrez, Guillermo
    Birkenfeld, Andreas L.
    Lawatscheck, Robert
    Scott, Charlie
    Rohwedder, Katja
    Rossing, Peter
    DIABETES, 2023, 72
  • [39] The effect of SGLT2i on the GH/IGF1 axis in newly diagnosed male T2D patients – a prospective, randomized case–control study
    Jing Lin
    Liqin Zhan
    Zheng Chen
    Xiaying Lin
    Rongfeng Zhu
    Endocrine, 2024, 84 : 203 - 212
  • [40] Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD A Network Meta-Analysis
    Luo, Xiaoling
    Xu, Jing
    Zhou, Shoulian
    Xue, Cheng
    Chen, Zewei
    Mao, Zhiguo
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (08): : 1019 - 1030
12345